Trial Profile

A randomized placebo-controlled, Phase 1b pharmacokinetic/pharmacodynamic trial of AM-201 co-administration with olanzapine in Antipsychotic-Induced Weight Gain.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Betahistine (Primary) ; Olanzapine
Indications Somnolence; Weight gain
Focus Proof of concept; Therapeutic Use
Sponsors Altamira Therapeutics; Auris Medical

Most Recent Events

26 May 2020 According to an Auris Medical media release, the company to disclose detailed results from the study in a scientific journal.
26 May 2020 Primary endpoint (Reduction in weight gain at 30mg) has been met, according to an Auris Medical media release.
26 May 2020 Positive top-line results presented in an Auris Medical Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com